Enantioselective synthesis of 2-ethyl-2,3-dihydrobenzofuran carboxylic acid, direct precursor of (+)-efaroxan, from a Baylis-Hillman adduct

Tetrahedron Letters

Volumn 46, Issue 38, 2005, Pages 6477-6481

  De Carvalho E Silveira, Gabriel P ^a   Coelho, Fernando ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Asymmetric synthesis; Baylis Hillman; Dihydrobenzofuran; Efaroxan; Heterocycles

Indexed keywords

2 ETHYL 2,3 DIHYDROBENZOFURAN CARBOXYLIC ACID; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; DIHYDROBENZOFURAN DERIVATIVE; EFAROXAN; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; BAYLIS HILLMAN REACTION; CHEMICAL PROCEDURES; CHEMICAL REACTION; DEGENERATIVE DISEASE; ENANTIOSELECTIVITY; MIGRAINE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARKINSON DISEASE;

EID: 23844528617     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2005.07.099     Document Type: Article

References (52)

1. S. Regunathan, and D.J. Reis Annu. Rev. Pharmacol. Toxicol. 36 1996 511 544
2. R.M. Eglen, A.L. Hudson, D.A. Kendall, D.J. Nutt, N.G. Morgan, V.G. Wilson, and M.P. Dillon Trends Pharmacol. Sci. 19 1998 381 390
3. To know more about the indication of efaroxan for the treatment of Parkinson disease see: Colpaert, F.; Briley, M.; Imbert, T. WO Patent 00145 1995.
4. Chem. Abstr. 122 1995 123150
5. For the use of efaroxan in the treatment of Alzheimer disease, see: Colpaert, F.; Briley, M.; Imbert, T. WO Patent 01791 1995.
6. Chem. Abstr. 122 1995 151400
7. M. Yoshida, and P.S. Mariano J. Org. Chem. 61 1996 4439 4449
8. N.G. Morgan Exp. Opin. Invest. Drugs 8 1999 575
9. N.G. Morgan, S.L.F. Chan, M. Mourtada, L. Monks, and C.A. Ramsden Ann. NY Acad. Sci. 881 1999 217 228
10. Chapleo, C.; Doxey, J. C.; Stillings, M. R. WO Patent 05171, 1992.
11. Chem. Abstr. 117 1992 131200
12. To some insights into the action mechanism of insulin, see: E. Laborde, and V.P. Manchem Curr. Med. Chem. 9 2002 2231 2242
13. For the determination of the absolute stereochemistry of the biologically active (R)-efaroxan, see: C. Belin, A. Chauvet, J.M. Leloup, J.P. Ribet, and J.L. Maurel Acta Crystallogr. C51 1995 2439 2441
14. For the racemic synthesis of efaroxan, see: C.R. Edwards, M.J. Readhead, and N.J. Tweddle J. Heterocycl. Chem. 24 1987 495 496
15. P. Mayer, P. Brunel, and T. Imbert Bioorg. Med. Chem. Lett. 9 1999 3021 3022
16. K. Couture, V. Gouverneur, and C. Mioskowski Bioorg. Med. Chem. Lett. 9 1999 3023 3026
17. J. Clews, N.G. Morgan, and C.A. Ramsden J. Heterocycl. Chem. 38 2001 519 521
18. C.B. Chapleo, P.L. Myers, R.C.M. Butler, J.A. Davis, J.C. Doxey, S.D. Higgins, M. Myers, A.G. Roach, C.F.C. Smith, M.R. Stillings, and A.P. Welbourn J. Med. Chem. 27 1984 570 576
19. Mioskowski, C.; Gouverneur, V.; Couture, K.; Lesimple, P.; Autret, J.-M. WO Patent 15624, 2000.
20. Chem. Abstr. 132 2000 222438
21. For an example of the synthesis of an efaroxan derivative, see: P. Mayer, C. Loubat, and T. Imbert Heterocycles 48 1998 2529 2534
22. For some examples of the resolution of racemic dihydrobenzofuran carboxylic acid, see: Imbert, T.; Mayer, P. WO Patent 35682 1996.
23. Chem. Abstr. 126 1997 59852
24. For the asymmetric synthesis of (R)-efaroxan, see: Mayer, P.; Imbert, T.; Couture, K.; Gouverneur, V.; Mioskowski, C. WO Patent 0002836, 2000.
25. Chem. Abstr. 132 2000 93199
26. For a recent example that demonstrates the potentiality of the Baylis-Hillman adduct in the total synthesis of antibiotics, see: C.R. Mateus, and F.C. Coelho J. Braz. Chem. Soc. 16 2005 386 396 (available free of charges at http://jbcs.sbq.org.br/online/2005/vol16_n3A/11-238-04.pdf )
27. For comprehensive reviews on the Baylis-Hillman reaction see: D. Basavaiah, A.J. Rao, and T. Satyanarayama Chem. Rev. 103 2003 811 891
28. W.P. Almeida, and F. Coelho Quim. Nova 23 2000 98 105
29. Chem. Abstr. 132 2000 236562e
30. E. Ciganek Org. React. 51 1997 201
31. D. Basavaiah, P.D. Rao, and R.S. Hyma Tetrahedron 52 1996 8001 8062
32. For some new insights about the mechanism of the Baylis-Hillman reaction see: L.S. Santos, C.H. Pavam, W.P. Almeida, F. Coelho, and M.N. Eberlin Angew. Chem., Int. Ed. 43 2004 4330 4333
33. K.E. Price, S.J. Broadwater, B.J. Walker, and D.T. McQuade J. Org. Chem. 70 2005 3980 3987
34. V.K. Aggarwal, S.Y. Fulford, and G.C. Llyod-Jones Angew. Chem., Int. Ed. 44 2005 1706 1708
35. W.P. Almeida, and F. Coelho Tetrahedron Lett. 39 1998 8609 8612
36. F. Coelho, W.P. Almeida, D. Veronese, E.C.S. Lopes, G.P.C. Silveira, R.C. Rossi, and C.H. Pavam Tetrahedron 58 2002 7437 7447
37. For a recent discussion about the mechanism of cuprate addition, see: S. Woodward Chem. Soc. Rev. 29 2000 393 401 and reference cited therein
38. M. Yamanaka, and E. Nakamura Organometallics 20 2001 5675 5681
39. There are in the literature some controversies concerning the mechanism of the 1,4-addition of organocuprate reagent on α,β-unsaturated compounds. Based on available theoretical evidences, compound 12 perhaps could be formed as shown below. Further studies should be done to confirm this proposition.
40. B. Christenson, G. Hallnemo, and C. Ullenius Tetrahedron 47 1991 4739 4752
41. K.B. Sharpless, Y. Gao, R.M. Hanson, J.M. Klunder, S.Y. Ko, and H. Masamune J. Am. Chem. Soc. 109 1987 5765 5780
42. K.B. Sharpless, and P.R. Carlier J. Org. Chem. 54 1989 4016 4018
43. R.C. Rossi, and F. Coelho Tetrahedron Lett. 43 2002 2800 2897
44. S.V. Ley, J. Norman, W. Griffith, and S.P. Marsden Synthesis 1994 639 666
45. S.V. Ley, W. Griffith, G.P. Whitcombe, and A.D. White J. Chem. Soc. Chem. Commun. 1987 1625 1627
46. H.W. Pinnick, W.E. Childers, and S.B. Balkrishna Tetrahedron 37 1981 2091 2096
47. E. Dalcane J. Org. Chem. 51 1986 567 569
48. J. March Advanced Organic Chemistry 3rd ed. 1985 John Wiley & Sons New York Chapter 13, pp 576-607
49. For a recent example concerning the synthesis of dihydrobenzofurans, see: J.F. Kuethe, A. Wong, M. Journet, and I.W. Davies J. Org. Chem. 70 2005 3727 3729 and references cited therein
50. The synthesis of (S)-enantiomer of 2 has been recently reported using a different approach, see: Guo S., Yong T. WO Patent 010936 2004.
51. Chem. Abstr. 140 2004 145991
52. -1.